- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
| 27.03. | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
| 06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
| 05.03. | TScan Therapeutics files for $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.12.24 | Why Is TScan Therapeutics Stock Gaining Today? | 3 | Benzinga.com | ||
| 26.12.24 | TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium | - | RTTNews | ||
| 26.12.24 | TScan Therapeutics announces ~$30M direct offering | 1 | Seeking Alpha | ||
| 26.12.24 | TScan sichert sich 30 Millionen US-Dollar durch Optionsscheinverkauf an Lynx1 | 4 | Investing.com Deutsch | ||
| 26.12.24 | TScan secures $30 million through warrant sale to Lynx1 | 1 | Investing.com | ||
| 26.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium | 2 | GlobeNewswire (USA) | ||
| 23.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank | 1 | GlobeNewswire (USA) | ||
| 23.12.24 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.24 | The Analyst Landscape: 5 Takes On TScan Therapeutics | 1 | Benzinga.com | ||
| 10.12.24 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 05.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 102,60 | +1,18 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| MEDIGENE | 0,154 | -13,52 % | PTA-AFR: Medigene AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Medigene AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Medigene AG: Vorabbekanntmachung... ► Artikel lesen | |
| AMGEN | 242,00 | -1,33 % | Amgen-Aktie: Kurs fällt ab (237,5811 €) | Das Wertpapier von Amgen notiert heute ein wenig leichter. Die Aktie notiert derzeit bei 269,98 US-Dollar. Für die Amgen-Aktie steht gegenwärtig ein Abschlag von 4,48 Prozent zu Buche. Das Wertpapier... ► Artikel lesen | |
| BIOFRONTERA | 2,490 | +2,89 % | EQS-HV: Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.2025 in Köln mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Biofrontera AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.2025 in Köln mit dem... ► Artikel lesen | |
| BIOGEN | 104,45 | +0,19 % | Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia | ||
| REGENERON PHARMACEUTICALS | 518,60 | 0,00 % | Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment | WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth... ► Artikel lesen | |
| EDITAS MEDICINE | 1,341 | -2,40 % | Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition | Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.... ► Artikel lesen | |
| GALAPAGOS NV | 22,400 | +0,09 % | Galapagos NV: Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts | First U.S. patient dosed in ATALANTA-1 study of GLPG5101
Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development... ► Artikel lesen | |
| IMMATICS | 3,892 | -2,36 % | Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting | Houston, Texas and Tuebingen, Germany, April 23, 2025 - Immatics N.V.(NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of... ► Artikel lesen | |
| AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,250 | -6,02 % | Autolus Therapeutics plc - 8-K, Current Report | ||
| IGM BIOSCIENCES | 1,220 | +3,39 % | IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs | - Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December... ► Artikel lesen | |
| ONCOPEPTIDES | 0,173 | -2,82 % | Oncopeptides AB: New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients | Stockholm, April 16, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further... ► Artikel lesen | |
| AVACTA | 0,336 | -2,89 % | Avacta Group PLC - Issue of Equity and Total Voting Rights | ||
| DERMATA THERAPEUTICS | 0,788 | -1,70 % | Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks | - Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI... ► Artikel lesen |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,635 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.
